Eye injection showdown: which treatment lasts longer?
NCT ID NCT04101877
Summary
This study compares two similar eye injection treatments for wet age-related macular degeneration, a leading cause of vision loss in older adults. Researchers want to see if one treatment (bevacizumab) requires more frequent injections than the other (aflibercept) to maintain the same vision benefits over two years. The study also measures vision quality, eye health, treatment costs, and how the treatments affect daily life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology
Mölndal, Sweden
Conditions
Explore the condition pages connected to this study.